Blurton-Jones lab attends Emerging Scientists Symposium at UCI

The UCI MIND trainee-led organization ReMIND held its annual Emerging Scientists Symposium at the UCI Student Center. This yearly event gives UCI MIND graduate students, medical students, and post-doctoral scholars opportunities to get out of the laboratory to present their work through posters and oral presentations, to network with and learn from each other, and to generally stay excited about research and the progress we are making toward understanding and discovering solutions for Alzheimer’s disease and related disorders (ADRD) research. Congratulations to Zahara Keulen, Dr. Ghazaleh Eskandari-Sedighi, and Dr. Jean Paul Chadarevian on your selection and presentations!

Read more about this important event: https://mind.uci.edu/remind_train/

Chadarevian et al. publish in Neuron

Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy

Microglia replacement strategies are increasingly being considered for the treatment of primary microgliopathies like adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). However, available mouse models fail to recapitulate the diverse neuropathologies and reduced microglia numbers observed in patients. In this study, we generated a xenotolerant mouse model lacking the fms-intronic regulatory element (FIRE) enhancer within Csf1r, which develops nearly all the hallmark pathologies associated with ALSP. Remarkably, transplantation of human induced pluripotent stem cell (iPSC)-derived microglial (iMG) progenitors restores a homeostatic microglial signature and prevents the development of axonal spheroids, white matter abnormalities, reactive astrocytosis, and brain calcifications. Furthermore, transplantation of CRISPR-corrected ALSP-patient-derived iMG reverses pre-existing spheroids, astrogliosis, and calcification pathologies. Together with the accompanying study by Munro and colleagues, our results demonstrate the utility of FIRE mice to model ALSP and provide compelling evidence that iMG transplantation could offer a promising new therapeutic strategy for ALSP and perhaps other microglia-associated neurological disorders.

MBJ Lab attends Keystone Symposia

Dr. Jean Paul Chadarevian and Joia K. Capocchi attend 2024 Keystone Symposia on Neurodegeneration in Santa Fe, NM where Jean Paul presented, “Therapeutic potential of human microglia transplantation in a chimeric model of CSF1R-related leukoencephalopathy“.

MBJ Lab attends ISMND 2024 Conference

Dr. Blurton-Jones (Examining the therapeutic potentical of microglial transplantation in chimeric models of AD and FTD) and Dr. Davtyan (Human Monocytes remain transcrptionally and functionally distinct from microglia despite long-term brain engraftment) presented at the International Society of Molecular Neurodegeneration 2024 conference on aging, immunity, and peripheral factors in neurodegenerative disease in Seoul, Korea.